Tag: Vertex Pharma

All

Ivacaftor Safe in CF Infants Aged 1 to 4 Months

A phase 3 clinical trial, ivacaftor (Kalydeco, Vertex Pharma) was generally safe to administer to infants aged 1-month to <4-months old, according to research published in Journal of Cystic Fibrosis.

FDA Approves First CRISPR-based Therapy for Sickle Cell Disease
Health Canada OKs Trikafta for Younger Children With Cystic Fibrosis
FDA Grants Kalydeco Expanded Approval for Infants with Cystic Fibrosis
Trikafta triple-combo Therapy Safe for Cystic Fibrosis Patients Ages 6-11
Kaftrio One Step Closer to EU Expanded Approval for Cystic Fibrosis Patients
Top 10 Medical Innovations for 2021 Include Trikafta, Bubble CPAP
Vertex’s Cystic Fibrosis Pill Gets European Medicines Agency’s Backing

All

Cystic Fibrosis: Costs Forcing Parents to Argentina for Orkambi Generic

According to BBC UK, parents of children with cystic fibrosis have resorted to medical tourism to purchase a generic of the CF drug Orkambi, which is not available through the National Health Service in the UK.

Latest Trial Data on Vertex CF Therapies and New Combos Show Benefits
Vertex Reports Very Positive Ph1/Ph2 Data on Triple Therapies for CF
Vertex Buys Experimental Cystic Fibrosis Drug
CF Drug Orkambi Will Top $1B in Sales This Year
FDA Approves Orkambi, New Treatment for Cystic Fibrosis
Corbus Looks to Take on Vertex with Experimental CF Drug

All

FDA Approves Kalydeco for CF Patients with the R117H Mutation

Over 3,100 people in North America, Europe and Australia with the CF R117H mutation will have a new treatment option with the new Kalydeco approval.

Vertex Files for US and Europe Approval of Combination Drug for CF
Vertex Pharmaceuticals’ Kalydeco Wins FDA Panel Backing
Vertex CF Drug Combo Significantly Improves Lung Function
FDA Approves Expanded Kalydeco Use for Cystic Fibrosis
Kalydeco Wins The Wall Street Journal’s 2012 Technology Innovation Award
Cystic Fibrosis Foundation and Vertex to Brief Congress on Cutting-Edge Venture-Philanthropy Model

Tag: Vertex Pharma

All

Ivacaftor Safe in CF Infants Aged 1 to 4 Months

FDA Approves First CRISPR-based Therapy for Sickle Cell Disease

Health Canada OKs Trikafta for Younger Children With Cystic Fibrosis

FDA Grants Kalydeco Expanded Approval for Infants with Cystic Fibrosis

Trikafta triple-combo Therapy Safe for Cystic Fibrosis Patients Ages 6-11

Kaftrio One Step Closer to EU Expanded Approval for Cystic Fibrosis Patients

Top 10 Medical Innovations for 2021 Include Trikafta, Bubble CPAP

Vertex’s Cystic Fibrosis Pill Gets European Medicines Agency’s Backing

All

Cystic Fibrosis: Costs Forcing Parents to Argentina for Orkambi Generic

Latest Trial Data on Vertex CF Therapies and New Combos Show Benefits

Vertex Reports Very Positive Ph1/Ph2 Data on Triple Therapies for CF

Vertex Buys Experimental Cystic Fibrosis Drug

CF Drug Orkambi Will Top $1B in Sales This Year

FDA Approves Orkambi, New Treatment for Cystic Fibrosis

Corbus Looks to Take on Vertex with Experimental CF Drug

All

FDA Approves Kalydeco for CF Patients with the R117H Mutation

Vertex Files for US and Europe Approval of Combination Drug for CF

Vertex Pharmaceuticals’ Kalydeco Wins FDA Panel Backing

Vertex CF Drug Combo Significantly Improves Lung Function

FDA Approves Expanded Kalydeco Use for Cystic Fibrosis

Kalydeco Wins The Wall Street Journal’s 2012 Technology Innovation Award

Cystic Fibrosis Foundation and Vertex to Brief Congress on Cutting-Edge Venture-Philanthropy Model

Sorry, No Posts Found

Respiratory Therapy

Our Parent Company

Key Resources

Helpful Links